Dual inhibition of EGFR and mTOR pathways in small cell lung cancer

por Schmid, K, Bago-Horvath, Z, Berger, W, Haitel, A, Cejka, D, Werzowa, J, Filipits, M, Herberger, B, Hayden, H, Sieghart, W
Publicado 2010

Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry

por Singer, C.F., Jahn, S.W., Rudas, M., Bago-Horvath, Z., Fitzal, F., Abete, L., Moinfar, F., Gnant, M., Filipits, M.
Publicado 2022

Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival

por Wimmer, K., Bolliger, M., Bago-Horvath, Z., Steger, G., Kauer-Dorner, D., Helfgott, R., Gruber, C., Moinfar, F., Mittlböck, M., Fitzal, F.
Publicado 2019

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer

por Exner, R, Bago-Horvath, Z, Bartsch, R, Mittlboeck, M, Retèl, V P, Fitzal, F, Rudas, M, Singer, C, Pfeiler, G, Gnant, M, Jakesz, R, Dubsky, P
Publicado 2014

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

por Zagouri, F, Bago-Horvath, Z, Rössler, F, Brandstetter, A, Bartsch, R, Papadimitriou, C A, Dimitrakakis, C, Tsigginou, A, Papaspyrou, I, Giannos, A, Dimopoulos, M-A, Filipits, M
Publicado 2013

Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors

por Berghoff, A S, Bago-Horvath, Z, Ilhan-Mutlu, A, Magerle, M, Dieckmann, K, Marosi, C, Birner, P, Widhalm, G, Steger, G G, Zielinski, C C, Bartsch, R, Preusser, M
Publicado 2012

Prognostic impact of breast cancer subtypes in elderly patients

por Bergen, E. S., Tichy, C., Berghoff, A. S., Rudas, M., Dubsky, P., Bago-Horvath, Z., Mader, R. M., Exner, R., Gnant, M., Zielinski, C. C., Steger, G. G., Preusser, M., Bartsch, R.
Publicado 2016

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

por Bartsch, R, Berghoff, A, Pluschnig, U, Bago-Horvath, Z, Dubsky, P, Rottenfusser, A, DeVries, C, Rudas, M, Fitzal, F, Dieckmann, K, Mader, R M, Gnant, M, Zielinski, C C, Steger, G G
Publicado 2012

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort

por Dubsky, P., Van't Veer, L., Gnant, M., Rudas, M., Bago-Horvath, Z., Greil, R., Lujinovic, E., Buresch, J., Rinnerthaler, G., Hulla, W., Moinfar, F., Egle, D., Herz, W., Dreezen, C., Frantal, S., Filipits, M.
Publicado 2020

ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6

por Filipits, M., Rudas, M., Singer, C.F., Fitzal, F., Bago-Horvath, Z., Greil, R., Balic, M., Lax, S.F., Halper, S., Hulla, W., Wu, N.C., Liu, X., Weidler, J., Bates, M., Hlauschek, D., Gnant, M., Dubsky, P.
Publicado 2021

Brain metastases free survival differs between breast cancer subtypes

por Berghoff, A, Bago-Horvath, Z, De Vries, C, Dubsky, P, Pluschnig, U, Rudas, M, Rottenfusser, A, Knauer, M, Eiter, H, Fitzal, F, Dieckmann, K, Mader, R M, Gnant, M, Zielinski, C C, Steger, G G, Preusser, M, Bartsch, R
Publicado 2012